Frontiers in Oncology (Nov 2022)

Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia

  • Lenghe Zhang,
  • Lenghe Zhang,
  • Lijuan Zhou,
  • Yulian Wang,
  • Chao Li,
  • Pengjun Liao,
  • Liye Zhong,
  • Suxia Geng,
  • Peilong Lai,
  • Peilong Lai,
  • Xin Du,
  • Xin Du,
  • Jianyu Weng,
  • Jianyu Weng

DOI
https://doi.org/10.3389/fonc.2022.1057153
Journal volume & issue
Vol. 12

Abstract

Read online

Identifying subgroups of T-cell acute lymphoblastic leukemia (T-ALL) with poor survival will significantly influence patient treatment options and improve patient survival expectations. Current efforts to predict T-ALL survival expectations in multiple patient cohorts are lacking. A deep learning (DL)-based model was developed to determine the prognostic staging of T-ALL patients. We used transcriptome sequencing data from TARGET to build a DL-based survival model using 265 T-ALL patients. We found that patients could be divided into two subgroups (K0 and K1) with significant difference (P< 0.0001) in survival rate. The more malignant subgroup was significantly associated with some tumor-related signaling pathways, such as PI3K-Akt, cGMP-PKG and TGF-beta signaling pathway. DL-based model showed good performance in a cohort of patients from our clinical center (P = 0.0248). T-ALL patients survival was successfully predicted using a DL-based model, and we hope to apply it to clinical practice in the future.

Keywords